Cargando…
Curcumin Formulations and Trials: What’s New in Neurological Diseases
Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectatio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698610/ https://www.ncbi.nlm.nih.gov/pubmed/33217959 http://dx.doi.org/10.3390/molecules25225389 |
_version_ | 1783615871267110912 |
---|---|
author | Gagliardi, Stella Morasso, Carlo Stivaktakis, Polychronis Pandini, Cecilia Tinelli, Veronica Tsatsakis, Aristides Prosperi, Davide Hickey, Miriam Corsi, Fabio Cereda, Cristina |
author_facet | Gagliardi, Stella Morasso, Carlo Stivaktakis, Polychronis Pandini, Cecilia Tinelli, Veronica Tsatsakis, Aristides Prosperi, Davide Hickey, Miriam Corsi, Fabio Cereda, Cristina |
author_sort | Gagliardi, Stella |
collection | PubMed |
description | Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline. |
format | Online Article Text |
id | pubmed-7698610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76986102020-11-29 Curcumin Formulations and Trials: What’s New in Neurological Diseases Gagliardi, Stella Morasso, Carlo Stivaktakis, Polychronis Pandini, Cecilia Tinelli, Veronica Tsatsakis, Aristides Prosperi, Davide Hickey, Miriam Corsi, Fabio Cereda, Cristina Molecules Review Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline. MDPI 2020-11-18 /pmc/articles/PMC7698610/ /pubmed/33217959 http://dx.doi.org/10.3390/molecules25225389 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gagliardi, Stella Morasso, Carlo Stivaktakis, Polychronis Pandini, Cecilia Tinelli, Veronica Tsatsakis, Aristides Prosperi, Davide Hickey, Miriam Corsi, Fabio Cereda, Cristina Curcumin Formulations and Trials: What’s New in Neurological Diseases |
title | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
title_full | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
title_fullStr | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
title_full_unstemmed | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
title_short | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
title_sort | curcumin formulations and trials: what’s new in neurological diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698610/ https://www.ncbi.nlm.nih.gov/pubmed/33217959 http://dx.doi.org/10.3390/molecules25225389 |
work_keys_str_mv | AT gagliardistella curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT morassocarlo curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT stivaktakispolychronis curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT pandinicecilia curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT tinelliveronica curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT tsatsakisaristides curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT prosperidavide curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT hickeymiriam curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT corsifabio curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT ceredacristina curcuminformulationsandtrialswhatsnewinneurologicaldiseases |